Hillstream Biopharma (NASDAQ:CNTN) Issues Earnings Results

Hillstream Biopharma (NASDAQ:CNTN – Get Free Report) issued its quarterly earnings data on Monday. The company reported ($0.16) earnings per share (EPS) for the quarter, FiscalAI reports. The business had revenue of $3.05 million for the quarter.

Hillstream Biopharma Stock Down 4.1%

Shares of CNTN stock opened at $1.64 on Tuesday. The stock has a market cap of $130.68 million, a price-to-earnings ratio of -3.28 and a beta of 1.49. The business’s fifty day moving average is $2.07 and its 200 day moving average is $2.62. Hillstream Biopharma has a twelve month low of $1.60 and a twelve month high of $5.83.

Analyst Ratings Changes

CNTN has been the subject of several research analyst reports. Weiss Ratings cut shares of Hillstream Biopharma from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday. Wall Street Zen cut shares of Hillstream Biopharma from a “hold” rating to a “sell” rating in a research report on Saturday. One analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, the stock has an average rating of “Sell”.

View Our Latest Stock Analysis on CNTN

About Hillstream Biopharma

(Get Free Report)

Hillstream BioPharma is a biotechnology company focused on developing experimental treatments for cancer, particularly drug-resistant tumors and cancer stem cells. Its research centers on ferroptosis, a form of cell death that may offer a way to attack cancer cells that are difficult to treat with existing therapies. The company’s development work includes its LION platform, which uses liposomal iron oxide nanoparticles to deliver iron to cancer cells and promote ferroptosis. Hillstream has described HSB-1216 as a potential cancer treatment based on this approach.

Featured Stories

Receive News & Ratings for Hillstream Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hillstream Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.